NCT00577356 - Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel

Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.

BIOLOGICAL

CG1940/CG8711

Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Trial Locations (1)

Virginia Mason Medical Center, Seattle